N/A
N=2,913
Telmisartan Tab Hypertension
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00890084 ↗Enrolled (actual)
2,913
Serious AEs
0.1%
Results posted
May 2012
Primary outcome: Primary: Percentage of Patients With Blood Pressure < 140/90 mm Hg — 69.6 Percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boehringer Ingelheim
- Primary completion
- Dec 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With Blood Pressure < 140/90 mm Hg |
69.6 | — |
| SECONDARY Percentage of Patients With Blood Pressure < 130/80 mm Hg |
13.2 | — |
| SECONDARY Absolute Blood Pressure Decrease |
23.2 | — |
| SECONDARY BP Response Rate (Drop of Systolic BP of 10mmHg or More) |
91.85 | — |
| SECONDARY Treatment Patterns |
4.7; 49.4; 3.3; 29.7; 12.6 | — |
| SECONDARY Change in Concomitant Antihypertensive Drugs Given at Study Entry |
13.6 | — |
| SECONDARY Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg |
11.7 | — |
| SECONDARY Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007 |
47.7 | — |
Summary
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
Eligibility Criteria
Inclusion criteria
Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in the usual way and in line with the SmPC and reimbursement criteria
Exclusion criteria
Contra-indications as in the Summary of Product Characteristics
Data sourced from ClinicalTrials.gov (NCT00890084). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.